China’s NEO Achieves World’s First Approved Commercial Brain Chip, Preceding Neuralink

Chinese biotech firm NEO has secured approval for the world’s first commercial brain‑chip. The clearance marks a milestone that predates similar efforts by Neuralink. The device is intended for therapeutic applications in neurology. Regulators evaluated the chip’s safety and efficacy before granting permission. NEO plans to begin clinical use of the technology in selected hospitals. The approval underscores China’s growing role in neurotechnology development. Industry analysts view the move as a boost for domestic medical innovation. Observers will watch how the chip performs in real‑world treatments.